GoldenGolden
Advanced Search
HiberCell

HiberCell

HiberCell is a New York-based biotechnology company developing therapeutics to prevent relapse and metastasis.

HiberCell is a biotechnology company that develops therapeutics for the prevention of relapse and metastasis. It is a company that focuses exclusively on therapeutically modulating the biology and mechanisms of tumor dormancy. The company is developing therapeutics that target dormant disseminated tumor cells from solid and liquid cancers and the company has the goal of preventing or delaying the recurrence of cancer.

The company was launched based on the research that was carried out at Mount Sinai’s Tisch Cancer Institute which shows that cancer recurrence is driven by dormant disseminated tumor cells, or DTCs, that can persist in the body for long period of time. The company aims to approach cancer as a systemic disease, detect and target DTCs to prevent or delay metastasis.

HiberCell is committed to developing therapeutic molecules that overcome foundational scientific barriers which prevent patients from living longer and ensure people live cancer-free. HiberCell has a multidisciplinary team that consists of cancer scientists, drug developers and venture capitalists who are leaders in their respective fields.

Timeline

June 29, 2021
HiberCell announces the appointment of Mark J. Mulvihill, Ph.D., as Chief Scientific Officer.
May 19, 2021
HiberCell raises a $67,400,000 series B round.
December 2, 2020
HiberCell announces the appointment of Joseph Talamo as chief financial officer and the promotion of Ari Nowacek, M.D., Ph.D., to chief business officer.

February 2019
HiberCell raises a $60,750,000 series A round from ARCH Venture Partners.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
June 29, 2021
BioSpace
HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, announced the appointment of Mark J. Mulvihill, Ph.D., as Chief Scientific Officer, who brings more than 20 years of experience in drug discovery and development with a focus on small molecule therapies.
June 9, 2021
BioSpace
IMV Announces Appointment of Jeremy R. Graff, Ph.D. as Chief Scientific Officer And Addition of Clinical Advisor - read this article along with other careers information, tips and advice on BioSpace
Kate Goodwin
May 26, 2021
BioSpace
Drug development requires solid funding. Here's who's standing on higher ground this week with fresh investment dollars.
Kate Goodwin
May 26, 2021
BioSpace
Drug development requires solid funding. Here's who's standing on higher ground this week with fresh investment dollars.
FinSMEs
May 22, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
HiberCell
January 13, 2021
www.prnewswire.com:443
/PRNewswire/ -- HiberCell, a biotechnology company developing novel therapeutics for cancer relapse and metastasis, today announced an agreement with Biodesix,...
Alex Keown
December 4, 2020
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
BioSpace
December 2, 2020
BioSpace
HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, announced the appointment of Joseph Talamo as chief financial officer and the promotion of Ari Nowacek, M.D., Ph.D., to chief business officer.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.